(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 December 2000 (28.12.2000)

PCT

(10) International Publication Number
WO 00/78247 A1

(51) International Patent Classification[6]: A61F 2/02, A61K 9/20, 9/48, 9/64

(21) International Application Number: PCT/US99/13821

(22) International Filing Date: 18 June 1999 (18.06.1999)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant: **BAKER NORTON PHARMACEUTICALS, INC.** [US/US]; 4400 Biscayne Boulevard, Miami, FL 33137 (US).

(72) Inventors: **GUTIERREZ-ROCCA, Jose, C.**; 9816 N.W. 32nd Street, Miami, FL 33172 (US). **CACACE, Janice, L.**; 527 N.E. 57th Street, Miami, FL 33137 (US). **SELIM, Sami**; 17 Colonial, Irvine, CA 92720 (US). **TESTMAN, Robert**; 1455 Canyon Crest Drive, Corona, CA 91720 (US). **RUTLEDGE, J., Michael**; 5441 Fieldstone Road, Riverdale, NY 10471 (US).

(74) Agents: **KRUMHOLZ, Arnold, H.** et al.; Lerner, David, Littenberg, Krumholz & Mentlik, LLP, 600 South Avenue West, Westfield, NJ 07090 (US).

(81) Designated States *(national)*: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *With international search report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 00/78247 A1

(54) Title: ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING TAXANES AND METHODS OF TREATMENT EMPLOYING THE SAME

(57) Abstract: Pharmaceutical compositions for oral administration to mammalian subjects comprise a taxane or taxane derivative (e.g., paclitaxel or docetaxel) as active ingredient and a vehicle comprising at least 30 % by weight of a carrier for the taxane, said carrier having an HLB value of at least about 10. The compositions may also comprise 0 - 70 % of a viscosity-reducing co-solubilizer. The compositions may be incorporated into conventional oral pharmaceutical dosage forms, or can be in the form of a two-part medicament wherein the first part includes the taxane in a solubilizing vehicle and the second part comprises a carrier for the taxane to promote oral absorption. Methods of treatment of taxane- responsive disease conditions employing the novel compositions are also disclosed, whereby the compositions can be administered alone or in association with an oral bioavailability enhancing agent.